Home

Decheng Capital Management III (Cayman), LLC

CIK 1747821 · last filed 2025-08-25

Decheng Capital Management III (Cayman), LLC is a corporate insider who has filed 5 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing shows the insider sold $60.7K of BYSI on Aug 25, 2025. Across all open-market trades the lifetime net is +$28.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $227.9M across reported positions. The firm reports its address in Grand Cayman, E9. 25 SEC filings were submitted jointly with Decheng Capital China Life Sciences USD Fund III, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$227.92M

Companies

3

Total Filings

5

Lifetime Open-Market Net

$28.94M

Filer Profile

Reported Address
PO BOX 309
UGLAND HOUSE
GRAND CAYMAN, E9 KY1-1104
Phone
(345) 949-8066
State of Incorporation
Cayman Islands
Related Filers
Decheng Capital China Life Sciences USD Fund III, L.P. — 25 joint filings, latest 2025-10-20
Xiangmin Cui — 20 joint filings, latest 2025-10-20
Decheng Capital Global Healthcare Fund (Master), LP — 19 joint filings, latest 2025-10-20
Decheng Capital Global Healthcare GP, LLC — 19 joint filings, latest 2025-10-20
Decheng Capital China Life Sciences USD Fund II, L.P. — 18 joint filings, latest 2025-10-20
Attestor Capital Ltd — same reported address
Attestor Value Fund GP Ltd — same reported address
BGPT Trebia LP — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BYSI 10%+ Owner 1,913,734 $0.76 $1.46M -$60.7K 1 2025-08-25
ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted 10%+ Owner 5,347,744 $64.97 $347.44M $29.00M 3 2024-05-20
HLTH 10%+ Owner 8,192,468 $27.64 $226.46M $0 1 2021-09-30

Recent Filings

5 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-08-25 BYSI Sell (S) −34,260 -$60.7K EDGAR
2024-05-20 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Mixed −41,589,620 $0 EDGAR
2022-09-27 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Grant (A) +4,000,000 $29.40M EDGAR
2021-09-30 HLTH Conv (C) +16,384,936 $0 EDGAR
2021-09-21 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Buy (P) +3,085,106 $29.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.